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ABSTRACT
Diabetic patients have a 3-fold higher risk of developing atherosclerosis
and its clinical complications as compared to non-diabetic individuals. Part
of the cardiovascular risk associated with diabetes is probably due to
genetic determinants influencing both glucose homeostasis and the devel-
opment of atherosclerosis. However, type 2 diabetes frequently coexists
with other cardiovascular risk factors like arterial hypertension, central
obesity and dyslipidemia. Genetic variability affecting many areas such as
lipid and energy metabolisms, hypertension and haemodynamic mecha-
nisms, blood clotting homeostasis, inflammation, and matrix turnover in
the vascular wall will have an impact on the development of macrovascu-
lar complications in diabetic patients. Adiponectin is abundantly secreted
by adipocytes. It plays important roles in lipid and glucose metabolisms
and has direct anti-inflammatory and anti-atherogenic effects. In this
review, we summarize recent data from the literature suggesting an impli-
cation of allelic variations of the adiponectin gene (ADIPOQ) in the genet-
ic determinants of cardiovascular disease in diabetic subjects. (Arq Bras
Endocrinol Metab 2007;51/2:153-159)
Keywords: Genetics; Adiponectin; Macrovascular disease
RESUMO
O Gene da Adiponectina e o Risco Cardiovascular em Pacientes
com Diabetes Tipo 2: Uma Revisão das Evidiencias.
Os pacientes com diabetes apresentam risco três vezes maior de desen-
volverem aterosclerose e suas complicações quando comparados a indi-
víduos sem hiperglicemia. Parte desse risco associado ao diabetes é
provavelmente relacionado a determinantes genéticos que influenciam
tanto a homeostase glicídica quanto o desenvolvimento da aterosclerose.
Entretanto, o diabetes tipo 2 freqüentemente coexiste com outros fatores
de risco cardiovascular, tais como hipertensão arterial, obesidade central
e dislipidemia. A variabilidade genética interfere em várias áreas tais como
o metabolismo lipídico, o metabolismo energético, hipertensão, mecanis-
mos hemodinâmicos, mecanismos de coagulação, inflamação e na for-
mação da matriz na parede vascular, que podem estar envolvidos nas
complicações macrovasculares dos pacientes com diabetes. A adiponecti-
na é secretada com abundância pelos adipócitos. Apresenta importante
papel no metabolismo lipídico e glicídico, tendo ação direta tanto antiin-
flamatória quanto anti-aterogênica. Na atual revisão, nós resumimos os
dados recentes da literatura que sugerem uma implicação de variantes
alélicas do gene da adiponectina (ADIPOQ) que podem estar envolvidos na
determinação genética da doença cardiovascular em indivíduos com dia-
betes. (Arq Bras Endocrinol Metab 2007;51/2:153-159)
Descritores: Genética; Adiponectina; Doença macrovascular
revisão
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CARDIOVASCULAR DISEASE (CVD) is the leadingcause of mortality and morbidity in patients with
diabetes. As compared to non-diabetic individuals,
diabetic patients have a 3-fold higher risk of develop-
ing atherosclerosis and its clinical complications such
as stroke, myocardial infarction, and peripheral vascu-
lar disease (1). Atherosclerosis is a complex inflamma-
tory disease of large arteries in which the interaction of
immune, metabolic and haemodynamic mechanisms
results in asymmetric focal thickenings of the intima by
the accumulation of lipids, connective-tissue elements,
cells and debris (2,3). The atheroma lesion starts with
the accumulation and entrapment in the intima matrix
of apolipoprotein B-containing lipoproteins, namely
VLDL/LDL and Lp(a). These lipoproteins undergo
lipid oxidation and other modifications, by interaction
with cellular oxidative waste and various enzymes,
resulting in LDL particles that have pro-inflammatory
properties. They are able to induce the production of
adhesion molecules, chemokines, and growth factors
by the overlying endothelial cells, which results in the
recruitment to the vessel wall of monocytes and lym-
phocytes. Monocytes proliferate and differentiate into
macrophages that take up the modified LDL. These
cholesterol-engorged “foam cells” eventually undergo
necrosis or apoptosis, contributing their contents to a
necrotic core of lipids and cell debris. HDL particles
protect against atherosclerosis by inhibiting lipid oxi-
dation of LDL and by promoting cholesterol efflux
from macrophages, while lymphocytes contribute to
lesion development by the production of cytokines
and immunoglobulins. Eventually, smooth muscle
cells migrate from the media layer and proliferate.
They secrete the collagen that forms a fibrous cap
overlying the necrotic core of the lesion. Myocardial
infarction and stroke are usually caused by rupture or
erosion of the atheroma lesion, leading to the forma-
tion of a thrombus that result in acute stenosis of the
vessel. Mechanisms of atheroma stability and of the
haemostatic cascade are likely to modulate the clinical
outcome.
Atherosclerosis-related CVD involves thus a
large number of pathophysiological processes in many
different cell types and organs (3), and an increasing
list of risk factors influenced both by genetic and envi-
ronmental determinants have been identified (3).
Classical risk factors like arterial hypertension, central
obesity and dyslipidemia frequently coexist with dia-
betes and contribute to the increased prevalence of
CVD in diabetic patients. However, type 2 diabetes
seems to be an independent risk factor for CVD (4).
The molecular mechanisms linking type 2 diabetes and
accelerated atherosclerosis remain unclear (5). Several
metabolic dysfunctions associated with type 2 diabetes
have been proposed to play a role in atherosclerosis,
including hyperglycaemia, formation of advanced gly-
cation end-products, hyperinsulinemia, endothelial
dysfunction, platelet hyperaggregability, coagulation
abnormalities, increased oxidative stress and chronic
inflammation (5).
Family history is a major risk factor for CVD
(6), and both mendelian and complex inheritance are
involved in the familial clustering of the trait. Mono-
genic defects leading to accelerated atherosclerosis
have been described (3), but they only account for a
small percentage of patients with CVD. In most cases,
atherosclerosis is a multifactorial disorder resulting
form the simultaneous action of many unfavourable
alleles interacting with environmental determinants.
Studies in rodents suggest that as many as 100 genes
can influence the development of atherosclerotic
lesions (3,7).
Several recent studies (8-11), as well as many
abstracts presented in Diabetes meetings (12-16),
reported associations of variants in the ADIPOQ gene
encoding adiponectin with CVD in type 2 diabetic
patients. These studies differed greatly in sample size,
power and tested CVD outcome, and not many ful-
filled ideal criteria for the design of association studies
(17), notably regarding sample size. Allelic associa-
tions of these ADIPOQ variants with obesity, insulin
resistance and type 2 diabetes have been reported pre-
viously in many populations (18-20).
The aim of this review was to evaluate the liter-
ature published over 2004–2006 on the role of
adiponectin in the genetic determinants of macrovas-
cular complications in diabetic subjects. In the first
part of the review, an introduction on the basic mech-
anisms of action of adiponectin associated with cardio-
vascular protection will be presented.
ADIPONECTIN IMPLICATION IN THE PATHO-
PHYSIOLOGY OF CARDIOVASCULAR DISEASE
Adiponectin is a 244 amino acid protein containing
a collagen like fibrous domain and a globular C1q-
like C-terminal domain, and which is abundantly
secreted by adipocytes. Adiponectin, also previously
called Acrp30, apM1, GBP28, or AdipoQ, has struc-
tural homology with collagens VIII and X, comple-
ment factor C1q, and the TNF family. The protein
form the basic unit of a trimer, which self-associates
to form hexamers then multimers of high molecular
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weight. These heavier forms seem to be the most
active ones in relation to insulin sensitivity (21).
Moreover, adiponectin circulates as a full-length
protein as well as a proteolytic cleavage fragment
consisting of the globular C-terminal domain that
might have increased potency (22). Two adipo-
nectin receptors named AdipoR1 and AdipoR2 have
been identified (23). AdipoR1 is preferentially ex-
pressed in muscle as high-affinity receptor for globu-
lar adiponectin and low affinity for full-length
adiponectin, whereas AdipoR2 is abundantly found
in the liver and serves as intermediate-affinity recep-
tors for both forms of adiponectin. The major role
of adiponectin in lipid and glucose metabolisms can
be explained by activation of AMP-activated protein
kinase (AMPK) and stimulation of PPARα, which
lead to increased glucose uptake and oxidation of
fatty acids in skeletal muscle and decreased hepatic
glucose output (24).
Adiponectin has many protective actions in the
initiation and progression of atherosclerosis by means
of direct anti-inflammatory and anti-atherogenic
effects. It modulates the inflammatory response of
endothelial cells to oxidized LDL and the activation
of monocytes and macrophages by inhibiting TNFα
induced monocyte adhesion and the expression of
endothelial leukocyte adhesion molecule 1 (E se-
lectin), vascular cell adhesion molecule-1 (VCAM1)
and intracellular adhesion molecule-1 (ICAM1) in
endothelial cells (25). Adiponectin inhibits the trans-
formation from macrophages to foam cells by
decreasing the expression of class-A macrophage
scavenger receptor (26) and acyl-coenzyme A choles-
terol acyltransferase-1 (ACAT-1) (27). It also in-
hibits proliferation and migration of smooth muscle
cells and stimulates the production of nitric oxide
(NO) in endothelial cells. Moreover, serum adipo-
nectin levels are positively associated with both
endothelium-dependent and endothelium-indepen-
dent arterial vasodilatation. Recent results suggest
that it also might have direct protective effects aga-
inst ischemia in the heart. Adiponectin-KO mice sub-
mitted to surgical induction of ischemia and reperfu-
sion had increased myocardial infarct size, myocardial
apoptosis and TNFα production compared with
wild-type mice submitted to the same procedure
(28). Administration of adiponectin diminished
infarct size, apoptosis and TNFα production in both
groups of animal. These effects were mediated in car-
diac cells by the activation of AMPK signaling and by
cycloxygenase 2 (COX2) dependent production of
prostaglandin E2.
ADIPONECTIN LEVELS AND 
CARDIOVASCULAR DISEASE
Plasma levels of adiponectin are significantly decreased in
obese patients, and negatively correlated with BMI (29).
Type 2 diabetic patients have lower plasma adiponectin
concentrations than non-diabetic subjects, independent-
ly of BMI (30). In many studies, plasma levels of
adiponectin were found to be lower in patients with
coronary artery disease (CAD) than in age and BMI
adjusted control subjects. Hypoadiponectinemia defined
by the 25th percentile was associated with a 2-fold
increase in CAD prevalence in male subjects, after adjust-
ments for other risk factors (31). Even in type 2 diabet-
ic patients, those with CAD have lower adiponectin lev-
els than those without CAD. Although adiponectin lev-
els are increased in type 1 diabetic patients and in
patients with end-stage renal disease, hypoadiponectine-
mia is an independent predictor of cardiovascular events
in these patients (32). In a prospective study, men with
high plasma adiponectin levels without previous CVD
had lower risk of myocardial infarction than those with
medium or low levels (33). In type 2 diabetic men from
the same cohort, adiponectin was associated with a
decreased risk for CAD events (myocardial infarction
and coronary artery bypass surgery), this association
being mediated in part by effects of adiponectin on HDL
cholesterol levels (34). It has also been suggested that
low adiponectin levels are related to impaired catabolism
of VLDL-apoB particles, which increases the dyslipi-
demic effect of insulin resistance resulting mainly in
increased hepatic production of VLDL-ApoB (35).
However, a prospective case-control study failed to
demonstrate similar effects on CAD events in women,
despite adequate statistical power and though associa-
tions with CVD risk factors were found (36). Recently,
a large prospective study in men could not confirm the
strong associations previously reported between
adiponectin levels and CAD (37), and a meta-analysis of
seven studies suggested only a moderate association
(37). Moreover, in another study in men with CAD, a
paradoxical effect was observed, as higher adiponectin
levels were an independent predictor of both all-cause
mortality and cardiac mortality (38).
ALLELIC VARIATIONS IN THE ADIPONECTIN GENE
(ADIPOQ) AND CARDIOVASCULAR DISEASE
An increasing body of data suggests associations of
ADIPOQ variants with CVD in diabetic patients. Lac-
quemant and co-workers investigated associations with
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CAD of five SNPs (-11377C>G, -4041A>C, +45T>G,
+276G>T, +349A>G, +2019delA) in cohorts of
French and Swiss type 2 diabetic patients (9). Cases
consisted of 162 patients with CAD, defined by trans-
mural myocardial infarction or positive coronary
angiography performed because of clinical angina or
abnormal resting electrocardiogram. The criteria of
positivity for the coronary angiography were not
given. Controls consisted of 315 subjects with no his-
tory of angina pectoris and a normal resting electro-
cardiogram. An association between the +45T>G SNP
and CAD was observed in both cohorts separately, as
well as when the two groups were pooled. GG
homozygotes and GT heterozygotes combined pre-
sented an increased risk of CAD as compared to TT
homozygotes (OR: 2.0; 95% CI: 1.3–3.2; p= 0.02),
and this association was independent from other risk-
factors such as age, sex, BMI, duration of diabetes,
smoking, arterial hypertension, triglycerides and
HDL-cholesterol levels. No association was observed
individually with the other SNPs. However, haplotype
analyses showed the combination of the five SNPs
wild-type alleles to decrease CAD risk (OR: 0.5; 95%
CI: 0.3–0.7; p= 0.0006). Interestingly, in that study,
no association was observed between the SNPs and
components of the metabolic syndrome (BMI, blood
pressure, HDL-cholesterol and triglycerides).
Bacci and co-workers investigated the possible
role of two frequent SNPs (+45T>G and +276G>T) as
genetic markers of CAD in a cohort of Italian type 2
diabetic patients (8). Cases consisted of 142 patients
with CAD, defined either by previous myocardial
infarction or by the presence of a 50% reduction in
diameter of at least one major vessel at coronary
angiography. Control subjects consisted of 234
patients who had no symptoms and no ECG signs of
myocardial ischemia and a normal exercise ECG test
and/or coronary stenosis of less than 50% at angiogra-
phy. In those controls, screening of CAD had been
indicated because of the presence of peripheral vascu-
lar disease and/or more than two cardiovascular risk
factors. A significant association with CAD was
observed for the +276G>T SNP, with TT homozy-
gotes presenting a lower risk of CAD as compared to
carriers of other genotypes (OR of 0.13; 95% CI:
0.037–0.46, p= 0.002, after adjusting for potential
confounders such as age, sex, duration of diabetes,
smoking, HbA1c, lipid levels, systolic and diastolic
blood pressure, antihypertensive and antidyslipidemic
treatments, insulin therapy, and adiponectin levels).
No association with CAD was observed for the
+45T>G SNP.
Ohashi and colleagues examined associations of
the frequent +45T>G and +276G>T SNPs and of the
less frequent +517T>C (Ile164Thr) missense poly-
morphism with CAD in a cohort of Japanese subjects
(10). Cases consisted of 383 patients with CAD,
defined by the presence of a 75% stenosis of at least
one segment of a major coronary artery confirmed by
coronary angiography. The controls consisted of 368
subjects, matched for age and sex with cases, with no
history of angina or other atherosclerotic vascular dis-
eases, and normal exercise electrocardiogram stress
testing. This study was not restricted to subjects with
diabetes, but diabetic subjects represented 48% of
cases and 10% of controls. Subjects with CAD had
lower plasma levels of adiponectin as compared to
controls. The authors observed an increased frequency
of Ile-Thr heterozygosity at codon 164 in CAD cases
as compared to controls (2.9% vs. 0.8%, p< 0.05). No
Thr homozygotes were found. Of note, adiponectin
plasma levels in Thr-allele carriers were half as much
lower than in wild-type subjects. No differences in the
genotype frequencies of the other SNPs were observed
between the two groups.
Similar results were observed in larger prospec-
tive studies. Associations of five SNPs (-11365C>G,
-4034A>C, -3964A>G, +45T>G, +276G>T) with
CVD risk were examined in a prospective cohort of
diabetic men (11), including 239 CVD cases and 640
control subjects. CVD consisted of new cases of fatal
coronary heart disease, nonfatal myocardial infarction,
coronary artery bypass grafting or percutaneous trans-
luminal coronary angioplasty, fatal stroke, and nonfa-
tal stroke that had occurred between 1986 and 2000.
Diagnoses of myocardial infarction were confirmed by
reviewing medical records for symptoms plus typical
EKG changes, elevated levels of cardiac enzymes
and/or autopsy findings. Diagnosis of stroke was con-
firmed by reviewing medical records and required evi-
dence of a neurological deficit with sudden or rapid
onset that persists for more than 24 h or until death.
Individuals with CVD were older and more likely to
have a history of hypertension or hypercholesterolemia
than the control subjects. Mean plasma adiponectin
levels were comparable between the two groups. Here
again, a significant association with CVD was observed
for the +276G>T SNP, with TT homozygotes pre-
senting a lower risk of CVD as compared to carriers of
other genotypes (OR of 0.38; 95% CI: 0.18–0.79, p=
0.009, after adjusting for age, BMI, smoking, alcohol
consumption, physical activity, aspirin use, HbA1c,
and history of hypertension or hypercholesterolemia).
The addition of plasma adiponectin, lipids, and inflam-
Adiponectin and Macrovascular Complications of Diabetes
Ferrarezi et al.
156 Arq Bras Endocrinol Metab 2007;51/2  
 
matory markers to the model did not appreciably
change the results, and similar association was
observed if the outcome was restricted to CAD, with
stroke cases excluded. No associations were observed
with the other SNPs or in haplotype analysis.
More recently, the same authors have also
investigated associations of these SNPs with
adiponectin levels and CVD risk in a cohort of dia-
betic women (the Nurses’ Health Study) including
285 cases and 704 controls (39). CVD was defined
as in the previous study, plus cases of sudden death.
GG homozygotes for the -11365C>G polymor-
phism presented significantly decreased plasma
adiponectin levels as compared to C-allele carriers.
The -4034A>C variant was associated with increased
cardiovascular risk under a recessive mode (OR of
1.62 for C-allele homozygosity; 95% CI: 1.07–2.45,
p< 0.02). The association did not appreciably change
after adjustment for age, BMI, smoking, alcohol con-
sumption, physical activity, HbA1c, history of hyper-
tension and hypercholesterolemia, diabetes duration,
and postmenopausal hormone use. The haplotype
analysis indicated that a common haplotype possess-
ing the allele T of the +276G>T was associated with
a significantly lower CVD risk than the most com-
mon haplotype (OR of 0.70; 95%CI: 0.50–0.98, p=
0.039). A meta-analysis of five studies performed
with the results of +276G>T variant suggested that
T-allele homozygosity was associated with an ~45%
reduction in CVD risk (39).
Other studies from China, France, Korea,
Poland and the UK were presented in Diabetes meet-
ings and confirmed associations of the -1191G>A,
+45T>G and -276G>T SNPs with CAD or CVD in
diabetic patients from different populations (12-
16,40). These associations with CAD or CVD were
also confirmed in cohorts composed for a large part of
non-diabetic subjects (41-43).
CONCLUSIONS
This review on the genetics of CVD had a limited
scope, focusing only on recently published associa-
tion studies of the gene encoding adiponectin
(ADIPOQ) in patients with diabetes. Selected studies
with other candidate genes were reviewed elsewhere
(44). It is clear from studies in the general popula-
tion that genetic variability affecting many areas such
as lipid and energy metabolisms, hypertension and
haemodynamic mechanisms, blood clotting home-
ostasis, inflammation, and matrix turnover in the vas-
cular wall have an impact on cardiovascular risk
(2,3,45). This increasing list of processes, each
involving a large number of genes and proteins, illus-
trates the difficulty of approaching the genetics of
CVD. Moreover, the lack of easily accessible inter-
mediate phenotypes for many candidate genes makes
more difficult their evaluation.
The causes and mechanisms of the increased
cardiovascular risk observed in patients with diabetes
are still unclear (5). The genetic factors associated
with macrovascular complications of diabetes are
deemed to be substantially the same as those associ-
ated with atherosclerosis and its clinical complica-
tions in non-diabetic subjects. Acceleration of ather-
osclerosis would be due to processes resulting from
insulin deficiency, defective insulin action, and
hyperglycaemia or associated metabolic defects.
However, it is also possible that part of the cardio-
vascular risk associated with diabetes is due to genet-
ic determinants influencing both glucose homeosta-
sis and the development of atherosclerosis. There is
an increasing body of evidence that this is indeed the
case for adiponectin, even if the genetic mechanism
behind the associations of these silent or intronic
SNPs in the ADIPOQ gene with diabetes and/or
CVD remains unexplained. Linkage disequilibrium
with a functional mutation located elsewhere in the
ADIPOQ gene is a possible explanation. Different
SNPs are associated with different diabetes-related or
atherosclerosis-related phenotypes in different popu-
lations, suggesting variable degrees of linkage dise-
quilibrium of the SNPs with the putative functional
variant. The biology underlying these allelic associa-
tions is also currently unknown. A genotype-related
effect on serum adiponectin levels is not consistently
observed, and in some studies, associations with dia-
betes or CVD are independent of serum adiponectin
levels (8,11,20). It is noteworthy that present
adiponectin levels as reported in theses studies might
not be good indicators of levels when atherosclerosis
started to develop. Variation of adiponectin levels
over time with age and the effect of diabetes upon
this variation are unknown. Regarding atherosclero-
sis, it is also unclear whether adiponectin levels in the
vascular wall reflects serum concentrations, or if does
not, whether there is a genotype-related effect.
Moreover, adiponectin circulates in a wide range of
full-length and globular multimers that need to be
properly quantified. All these questions are waiting
for further investigations.
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